Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - naltrexone hydrochloride -

Canada - English - Health Canada

apotex inc - naltrexone hydrochloride - tablet - 50mg - naltrexone hydrochloride 50mg - opiate antagonists

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

duopharma (m) sdn. bhd. - naltrexone hydrochloride -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm) - naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. naltrexone hydrochloride tablets have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. naltrexone is contraindicated in: 1. patients receiving opioid analgesics. 2. patients currently dependent on opioids, including those currently maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). 3. patients in acute opioid withdrawal (see warnings ). 4. any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. 5. any individual with a history of sensitivity to naltrexone or any other components of this product. it is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. naltrexone is a pure opioid antagonist. it does not lead to physical or psychological dependence. tolerance to the opioid antagonist effect is not known to occur.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Malta - English - Medicines Authority

health house pharma ltd t/as p&d pharmaceuticals ltd 38 woolmer way, bordon, hampshire, gu35 9q, united kingdom - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - naltrexone hydrochloride - film-coated tablet - naltrexone hydrochloride 50 mg - other nervous system drugs

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - naltrexone hydrochloride -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - naltrexone hydrochloride (unii: z6375yw9sf) (naltrexone - unii:5s6w795cqm), bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (bmi) of: - 30 kg/m2 or greater (obese) or - 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). limitations of use: - the effect of contrave on cardiovascular morbidity and mortality has not been established. - the safety and effectiveness of contrave in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. contrave is contraindicated in - uncontrolled hypertension [see warnings and precautions (5.5)] - seizure disorder or a history of seizures [see warnings and precautions (5.3)] - use of other bupropion-containing products (including, but not limited to, wellbutrin, wellbutrin sr, wellbutrin xl, aplenzin and zyban) - bulimi